[Problem] To provide a non-aqueous percutaneously absorptive formulation in which, despite there being a small amount (2 mass% to 4 mass%) of a drug in an adhesive layer constituting the non-aqueous percutaneously absorptive formulation, the drug efficacy is sufficiently expressed, and which demonstrates sufficient adhesion and manufacturing suitability. [Solution] A non-aqueous percutaneously absorptive formulation comprising a support and an adhesive layer laminated on the support, wherein the adhesive layer contains: a non-steroid anti-inflammatory analgesic agent comprising a salt form of an alkali metal at 2 mass% to 4 mass% with respect to the total mass of the adhesive layer; a rosin ester derivative at 10 mass% to 30 mass% with respect to the total mass of the adhesive layer; and an inorganic acid.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; reagent paper for medical
purposes; adhesive tapes for medical purposes; gauze for
dressings; capsules for medicines; eyepatches for medical
purposes; ear bandages; menstruation tampons; menstruation
knickers; antiseptic cotton; adhesive bandages; dressing
materials; antiseptic liquid bandages; breast-nursing pads;
cotton swabs for medical purposes; composite materials for
dental purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations, namely, medical plasters, medicated compresses, herbal mud packs for therapeutic purposes, and sticking plasters for medical purposes; reagent paper for medical purposes; adhesive tapes for medical purposes; gauze for dressings; eyepatches for medical purposes; ear bandages; menstruation tampons; menstruation knickers; antiseptic cotton; bandages for skin wounds; materials for dressings, namely, medical dressing, wound dressing, self-adhesive dressing, first aid dressing, dressing for burns; antiseptic liquid bandages; breast-nursing pads; cotton swabs for medical purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, medical plasters, medicated compresses, herbal mud packs for therapeutic purposes, and medical sticking plasters; reagent paper for medical purposes; adhesive tapes for medical purposes; gauze for dressings; eyepatches for medical purposes; ear bandages; menstruation tampons; menstruation knickers; antiseptic cotton; bandages for skin wounds; dressing materials being gauze for dressings; antiseptic liquid bandages; breast-nursing pads; cotton swabs for medical purposes
An adhesive patch comprising: a support; at least a pressure-sensitive adhesive layer provided on the support; and a release liner attached on the pressure-sensitive adhesive layer so as to cover the surface of the pressure-sensitive adhesive layer, in which the support is a 3D patterned sheet characterized in that a plurality of protruded lines and recessed lines parallelly and linearly extending are formed inside and outside lines in a plurality of figures partitioned by the lines, walls of the protruded lines and recessed lines in some of the figures are formed to be inclined by different inclination angles with respect to a base part, and the protruded lines have different heights from the base part, serving as physical parameters of the protruded lines and recessed lines, toward a predetermined direction in the sheet.
[Problem] To provide an adhesive skin patch that uses, as a support body thereof, a 3D-patterned sheet of which the flexibility can be easily changed for each part requiring flexibility or stiffness, and which is made in view of an end product that would appeal to users' sensation or sensitivity such as touch feel and texture, such that the adhesive skin patch is not only highly designable but also has excellent usability when being used. [Solution] This adhesive skin patch is obtained by at least providing a pressure-sensitive adhesive layer over a support body and bonding a release liner on the pressure-sensitive adhesive layer so as to cover the surface thereof, wherein: the support body comprises a 3D-patterned sheet characterized by having a plurality of ridges and troughs formed so as to linearly extend in parallel to each other on both the inner side and the outer side of a plurality of graphic forms delineated by lines; in some of the graphic forms, the walls of the ridges and troughs are formed so as to be slanted at different inclination angles with respect to a base part; and the heights of the ridges from the base part, being one of the physical parameters of the ridges and troughs, vary in a prescribed direction within the plane of the sheet.
There is provided a novel compound having neurite-outgrowing activity that is useful for the prevention or the treatment of a neurodegenerative disease. A compound of Formula (I)
1-5 alkyl group, or a 5- or 6-membered ring aryl group optionally having 1 or 2 nitrogen atom(s), sulfur atom(s), or oxygen atom(s)], or a pharmaceutically or veterinary-medically acceptable salt of the compound.
A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
C07J 51/00 - Stéroïdes normaux à squelette du cyclopenta[a]hydrophénanthrène non modifié non prévus dans les groupes
8.
Adhesive material containing 5-methyl-1-phenyl-2-(1H)-pyridone
There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof.
A61L 15/16 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons
A61L 15/22 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des matériaux macromoléculaires
Provided are a silicate-based fluorescent material having excellent fluorescence intensity and a process for producing the fluorescent material. The process for producing a silicate-based fluorescent material is characterized by introducing into a vessel a starting-material powder comprising a compound containing at least one luminescent ion selected from Eu, Ce, Mn, and Tb and burning the starting-material powder while supplying gaseous SiOx (0.5≤x≤1.9, preferably 0.8≤x≤1.2). The starting-material powder preferably further contains at least one of alkali metal compounds, alkaline-earth metal compounds, magnesium compounds, and rare-earth compounds. The silicate-based fluorescent material preferably is M2SiO4:Eu2+ (wherein M is one or more elements selected from a group consisting of Ca, Sr, and Ba). Preferably, the burning is conducted in such a manner that SiOx is supplied to the starting-material powder in a gaseous atmosphere having a temperature of 1,200-1,700ºC and the starting-material powder is caused to undergo a gas-solid reaction at a temperature of 700-1,700ºC.
Disclosed is a novel compound having a neurite-outgrowing activity and is therefore useful for the prevention or treatment of neurodegenerative diseases. Specifically disclosed is a compound represented by formula (I) [wherein X represents OR or NR1R2; Y represents OH, NR3R4, -NHC(=NH)NHR5 or –NHC(=NH)R5; and Z represents a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, or a 5- to 6-membered aryl group which may have one or two atoms independently selected from a nitrogen atom, a sulfur atom and an oxygen atom] or a pharmaceutically or veterinarily acceptable salt thereof.
C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
There is provided an ultraviolet absorber having a strong absorptive capacity in the UVA range and an absorptive capacity in the UVB range to have an ultraviolet inhibitory effect in a wide range of wavelength, increasing in an ultraviolet absorptive capacity over the course of ultraviolet irradiation time in both the UVA and the UVB ranges and having an excellent solubility. An ultraviolet absorber comprising, as an active ingredient, a compound of General Formula I:
(where —OA is an alkoxy group) that exhibits an ultraviolet A wave absorptive capacity which increases over time and that has an ultraviolet B wave absorptive capacity.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 8/00 - Cosmétiques ou préparations similaires pour la toilette
C07C 69/76 - Esters d'acides carboxyliques dont un groupe carboxyle estérifié est lié à un atome de carbone d'un cycle aromatique à six chaînons
[PROBLEMS] The invention aims to provide a patch which is inhibited from the bending of the pharmaceutical preparation and from the adhesion of plaster areas to each other in application and which can be easily and simply applied nearly without failure. [MEANS FOR SOLVING PROBLEMS] A patch comprising a substrate, a plaster layer formed on the substrate, and a release paper lying on the plaster layer in such a way as to cover the nearly whole surface of the plaster layer, characterized in that sections different in bending resistance are formed in one substrate and a section having a bending resistance higher than those of the other sections is localized in an area where the plaster is to be first exposed in application, whereby the adhesion of plaster areas to each other is inhibited in application.
Disclosed is an adhesive material containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive material containing 5-methyl-1-phenyl-2-(1H)-pyridone comprises an active medicinal ingredient-containing layer, and is characterized in that the active medicinal ingredient-containing layer contains an oily base, a solvent (excluding glycerol and middle-chain fatty acid triglycerides), and 5-methyl-1-phenyl-2-(1H)-pyridone or a medically acceptable salt thereof.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
There is provided a medicated patch including 5-methyl-1-phenyl-2-(1H)-pyridone. A medicated patch comprising a percutaneously absorbable preparation layer, wherein the percutaneously absorbable preparation layer includes 5-methyl-1-phenyl-2-(1H)-pyridone or a pharmaceutically acceptable salt thereof as an active component, a dissolving agent and an aqueous base material (or a rubber-type base material), and the active component is contained in an amount of 0.1 to 30 mass % relative to the total amount of the percutaneously absorbable preparation layer.
Provided is a novel compound which is a sominone derivative represented by formula (1) or a salt thereof and which is useful as an agent for the prevention and treatment of neurological disease.
C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
[PROBLEMS] To provide a novel compound having excellent carcinostatic activity, a medicament useful for thermotherapy, and a thermotherapy method using the medicament. [MEANS FOR SOLVING PROBLEMS] A compound represented by formula (1): wherein R1 represents an alkyl group, a cyano group, an acyl group, and a hydroxyl group; and R2 represents a group represented by SiR3 wherein R represents a straight chain or branched chain alkyl group having 1 to 4 carbon atoms, and three R's may be the same or different, and a medicament for thermotherapy, comprising the compound as an active ingredient.
Disclosed is a neuronal cell death inhibitor having high efficacy. Specifically disclosed is a neuronal cell death inhibitor comprising a compound represented by the general formula (1) or a salt thereof. (1) wherein R1 represents a hydrogen atom or a hydroxyl group which may be substituted; R2 represents a hydrogen atom; R3 represents a hydrogen atom or a hydroxyl group which may be substituted; R4 represents a hydrogen atom or a hydroxyl group which may be substituted; R3 and R4 may together form an oxo group or a group represented by the formula -O-(CH2)n-O- [wherein n represents an integer of 2 to 4], or R2 and R4 may together form an unsaturated bond between carbon atoms to which R2 and R4 are attached; R5 represents a hydrogen atom or a lower alkyl group which may be substituted; R6, R7 and R8 independently represent a hydrogen atom, a hydroxyl group which may be substituted, an alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 307/77 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques
[PROBLEMS] To provide a novel ultraviolet absorber, which has an ultraviolet inhibitory activity in a wide wavelength range, that is, has a strong absorptive capacity in a UVA region and further has an absorptive capacity in a UVB region, has such a property that the ultraviolet absorptive capacity in the UVA and UVB regions increases with the cumulation of ultraviolet irradiation time, and has excellent solubility. [MEANS FOR SOLVING PROBLEMS] An ultraviolet absorber having a high ultraviolet A wave absorptive capacity comprising a novel ultraviolet absorptive compound represented by general formula I as an active ingredient: wherein -OA represents an alkoxy group.
C07C 69/736 - Éthers le groupe hydroxyle de l'ester étant éthérifié par un composé hydroxylé dont le groupe hydroxyle est lié à un atome de carbone d'un cycle aromatique à six chaînons
A61Q 17/04 - Préparations topiques pour faire écran au soleil ou aux radiationsPréparations topiques pour bronzer
A61Q 19/00 - Préparations pour les soins de la peau
C07C 67/14 - Préparation d'esters d'acides carboxyliques à partir d'halogénures d'acides carboxyliques
C09D 5/00 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, caractérisées par leur nature physique ou par les effets produitsApprêts en pâte
[PROBLEMS] To provide an ultraviolet absorptive compound that exhibits ultraviolet inhibitive action over a wide range of wavelength, having not only high absorptive power in the UVA region but also absorptive power in the UVB region as well, and that also excels in solubility, and provide a novel ultraviolet absorber that contains the compound as an active component, exhibiting high ultraviolet A-wave absorbing capability. [MEANS FOR SOLVING PROBLEMS] There is provided a novel ultraviolet absorptive compound that exhibits ultraviolet inhibitive action over a wide range of wavelength, having not only high absorptive power in the UVA region but also absorptive power in the UVB region as well and that also excels in solubility, which compound is any one of those of the general formula (I): [chemical formula 1] wherein -OA is an electron donating group. Further, there is provided an ultraviolet absorber that contains the above compound as an active component, exhibiting high ultraviolet A-wave absorbing capability.
C07C 69/736 - Éthers le groupe hydroxyle de l'ester étant éthérifié par un composé hydroxylé dont le groupe hydroxyle est lié à un atome de carbone d'un cycle aromatique à six chaînons
Disclosed is a medicated patch comprising 5-methyl-1-phenyl-2-(1H)-pyridone. Specifically disclosed is a medicated patch having a percutaneously absorbable preparation layer. The percutaneously absorbable preparation layer comprises 5-methyl-1-phenyl-2-(1H)-pyridone or a pharmaceutically acceptable salt thereof as an active ingredient, a dissolving agent and an aqueous base material (or a rubber-type base material), wherein the active ingredient is contained in an amount of 0.1 to 30 mass% relative to the total amount of the percutaneously absorbable preparation layer.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/12 - Kératolytiques, p. ex. préparations pour le traitement des verrues ou des cors
21.
Nonaqueous preparation for percutaneous absorption containing nonsteroidal anti-inflammatory analgesic
The present invention relates to nonaqueous preparation for percutaneous absorption prepared by laminating an adhesive layer comprising a nonsteroidal anti-inflammatory analgesic in an alkali metal salt form, and an inorganic acid which is strongly acidic compared with the nonsteroidal anti-inflammatory analgesic in a free form, together with a nonaqueous base, on a support. According to the present invention, drug-releasing characteristics and skin penetration in a nonaqueous preparation for percutaneous absorption can be improved because the addition of an inorganic acid in a nonaqueous base containing a drug in an alkali metal salt form leads to an improvement in the solubility of the drug in the base, and a good partitioning of the drug to skin surface. In addition, as the inorganic acid has no alcoholic hydroxy group in the structure, the inorganic acid does not react with the drug, therefore it causes no lowering in the stability of the drug by esterification.
A01N 43/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques
A percutaneous absorption type cerebral protective agent containing as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:
or a medically acceptable salt thereof in a base; a use of the compound as an active ingredient for the manufacture of a percutaneous absorption type pharmaceutical composition for protecting brain; and a method of protecting brain comprising administering to a patient the pharmaceutical composition as an active ingredient.
An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1:
50 means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations as well as
preparations and substances for sanitary purposes; plasters,
compresses, packs, bandages, sticking plasters, dressing
material.
